Vietnam Lung Cancer Therapeutics Market Report 2022 to 2030

Vietnam Lung Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Vietnam Lung Cancer Therapeutics Market will reach a value of $283 Mn from $149 Mn in 2022, growing at a CAGR of 8.3% during 2022-30. The Lung Cancer Therapeutics Market in Vietnam is dominated by a few domestic pharmaceutical companies such as Hau Giang Pharmaceutical, Traphaco, and Vietnam Pharmaceutical. The Lung Cancer Therapeutics Market in Vietnam is segmented into different types of cancer and different therapy types. Some of the major factors affecting the Vietnam lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies, and the presence of highly efficient drugs.

ID: IN10VNPH041 CATEGORY: Pharmaceuticals GEOGRAPHY: Vietnam AUTHOR: Dr. Vishwa Modhia

Buy Now

Vietnam Lung Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Vietnam Lung Cancer Therapeutics market will reach a value of $283 Mn from $149 Mn in 2022, growing at a CAGR of 8.3% during 2022-30.

Vietnam, a low–middle-income Southeast Asian country with a population of 96.5 Mn, is the 15th most populous country in the world. Since 2012, lung cancer has been the second most frequent cancer and the second leading cause of cancer deaths in Vietnam, with an anticipated 26,262 new cases and 23,797 cancer deaths in 2020. Lung cancer is the most prevalent cancer diagnosis in males and the fourth most common in women. Lobectomy is used as a surgical treatment option in 85 % to 95 % of instances; lobectomy and pneumonectomy account for 3.5 % and 0.5 %, respectively.

According to the latest WHO data published in 2020 Lung Cancers Deaths in Viet Nam reached 21,294 or 3.11% of total deaths. The age-adjusted Death Rate is 21.48 per 100,000 of the population ranks Viet Nam 46^th in the world. Vietnam's government spends 4.7% of its GDP on healthcare.

Vietnam Lung Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers

The use of radiation therapy for lung cancer is predicted to increase in Vietnam. Although the number of linear accelerators increased from 13 in 2010 to 58 in 2020, this is insufficient to meet existing demand. There are five comprehensive cancer centres, as follows: Vietnam National Cancer Hospital, Hanoi Oncology Hospital (North); Hue Oncology Hospital (Central); Ho Chi Minh City Oncology Hospital, and Cho Ray Hospital (South Vietnam). In addition, 70 oncology departments were housed in level I and II hospitals.

Although robotic-assisted thoracic surgery has recently been implemented in three hospitals, it is rarely used due to the high cost and only limited reimbursement by the NHI. In 1997, Vietnamese men had one of the highest smoking rates in the world, with a frequency of current smoking of 72.8 %, while women smoked at a rate of only 4.3 %. Vietnam's economy is prospering, with one of the region's strongest growth rates. Vietnam's large labour pool and low labour costs encourage corporate expansion. These aspects could boost the Vietnam Lung Cancer Therapeutics market.

Market Restraints

Existing barriers include high smoking rates, a lack of lung cancer screening programmes, restricted access to optimum therapy, and reimbursement limits. In Vietnam, flaws in the business climate, fueled by concerns about data transparency and corruption perceptions, can make doing business difficult. These factors may deter new entrants into the Vietnam Lung Cancer Therapeutics market.

Competitive Landscape

Key Players

Hau Giang Pharmaceutical: Hau Giang Pharmaceutical is a Vietnamese pharmaceutical company that produces and distributes a range of medicines, including those used in the treatment of lung cancer
Domesco Medical Import-Export Corporation: Domesco Medical is a Vietnamese pharmaceutical company that produces and distributes a range of medicines, including those used in the treatment of lung cancer
Ha Tay Pharmaceutical: Ha Tay Pharmaceutical is a Vietnamese pharmaceutical company that produces and distributes a range of medicines, including those used in the treatment of lung cancer
Traphaco: Traphaco is a Vietnamese pharmaceutical company that produces and distributes a range of medicines, including those used in the treatment of lung cancer
Vietnam Pharmaceutical Corporation: Vietnam Pharmaceutical is a state-owned Vietnamese pharmaceutical company that produces and distributes a range of medicines, including those used in the treatment of lung cancer

Recent Notable Updates

March 2022: Roche Pharma Vietnam and the HCM City Cancer Hospital struck an agreement to boost the hospital's medical staff's professional ability and to strengthen collaboration with domestic and international oncology organisations and specialists. The Memorandum of Understanding aims to improve diagnostic and therapeutic capacity, treatment, and patient support while also carrying out experience exchange among international organisations, implementation of key projects on breast, lung, and liver cancer, and the creation of a database for patient treatment and care.

Healthcare Policies and Reimbursement Scenarios

The regulation and reimbursement of lung cancer therapeutics in Vietnam are overseen by several entities, including the Ministry of Health and the Vietnam Social Security (VSS). The Vietnam social insurance sector has always accompanied the health sector and medical establishments to propose and implement measures to remove difficulties and obstacles for medical facilities such as adopting guidelines from authorities in implementing health insurance policies proactively and actively. To be eligible for reimbursement, lung cancer therapeutics must be included in the National List of Essential Medicines (NLEM), which is a list of drugs and medicines approved for reimbursement by the VSS.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Lung Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Small Cell Lung Cancer
Non-small Cell Lung Cancer
Lung Carcinoid Tumor

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
Immunotherapy
Chemotherapy
Others

By Type of Molecule (Revenue, USD Billion):

Small Molecules
Biologics

By Drug Class (Revenue, USD Billion):

Alkylating Agents
Antimetabolites
Multikinase Inhibitors
Mitotic Inhibitors
EGFR Inhibitors
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.